US Food and Drug Administration (USFDA) has concluded inspection at Shilpa Medicare’s Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla in the state of Telangana from August 29, 2019 to September 6, 2019.
The inspection concluded with two observations. There were no repeat observations or Data Integrity (DI) related observations.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
